提克萨吉维玛/西尔加维玛 (AZD7442/Evusheld) 能在接受活性化疗的血液恶性瘤患者中预防COVID19
Yoo Jin Lee1, Hyun-Ki Kim2, Youjin Kim1
1Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
Annals of hematology
|April 28, 2024
概括
提克萨吉维马布/西尔加维马布在患有血液性恶性瘤的患者中有效提升了抗体水平,在给药后显著增加. 这种COVID-19治疗方法表现出良好的安全性和潜在的预防严重疾病在这个弱势群体.
科学领域:
- 免疫学和传染病的研究
- 血液学和瘤学研究
背景情况:
- 患有血液恶性瘤的患者在接种疫苗后也面临COVID-19的严重风险.
- 在这个人群中,对单克隆抗体治疗的有效性,如tixagevimab/cilgavimab的真实数据至关重要.
研究的目的:
- 在接受化疗的血液性恶性瘤患者中,前性地评估tixagevimab/cilgavimab (AZD7442/Evusheld) 的现实世界管理和免疫性.
- 评估 tixagevimab/cilgavimab 在这种高风险群体中对症状和严重的 COVID-19 的安全性和潜在的保护作用.
主要方法:
- 94名因淋巴瘤,多发性骨髓瘤或急性白血病而接受活性化疗的患者接受了单剂量 tixagevimab/cilgavimab.
- 对抗SARS-CoV-2峰值 (anti-S) 和核体 (anti-N) 抗体标位的定量测量在基线和1,3,6个月后进行.
- 在整个6个月的随访期间,安全性和SARS-CoV-2感染率都受到监测.
主要成果:
- 提克萨吉维玛/西尔加维玛从基线 (997.05AU/mL) 的中位数抗S抗体水平显著增加到1个月后的峰值 (20,967.25AU/mL),在3个月和6个月后的持续水平 (p < 0.001).
- 治疗耐受性良好,没有报告任何重大安全问题.
- 在6个月的随访期间,13.8%的患者经历了记录的SARS-CoV-2感染,而20.2%的患者在6个月后表现出抗N阳性.
结论:
- 提克萨吉维马布/西尔加维马布的使用导致血液恶性瘤患者抗SARS-CoV-2抗体标位的强大和持续增加.
- 在这种免疫受损人群中,该疗法表现出了有利的安全性.
- 这些发现支持tixagevimab/cilgavimab在预防血液恶性瘤患者的症状和严重COVID-19的潜在效用.
相关概念视频
01:27Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
01:30Cancer Vaccines
359
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
359
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K